Pre-Launch Inventory — PDUFA Date Manufacturing
Recording the accounting treatment of drug product manufactured ahead of FDA approval in anticipation of a commercial launch.
| Account Name | Type | Debit ($) | Credit ($) |
|---|---|---|---|
| R&D Expense (Pre-Approval Inventory) | Expense (+) | 18,000,000.00 | - |
| Cash / Accounts Payable (CMO) | Asset/Liability (-) | - | 18,000,000.00 |
💡 Accountant's Note
Under IFRS (IAS 2 / IAS 38), inventory manufactured before regulatory approval cannot be capitalised as inventory unless regulatory approval is considered virtually certain. Without approval, there is no future economic benefit — the product would be scrapped. Best practice in pharma is to expense pre-approval inventory at-risk as R&D, or as inventory only if approval is virtually certain and the drug clearly meets the asset recognition criteria.
Practitioner & Systems Framework
💻 ERP Architecture
Pre-approval manufacturing costs are tracked on a dedicated project code in the ERP that is ring-fenced as 'at-risk inventory' or 'pre-approval R&D'. The decision to expense or capitalise is made at the point of manufacturing, based on the regulatory risk assessment. IFRS requires 'practically certain' of approval for capitalisation. In practice, most companies expense all pre-approval manufacturing as R&D (conservative policy) unless receiving a Complete Response Letter is considered remote and approval is imminent. At the point of approval, some companies reverse the expense and capitalise — though this reversal of previously expensed costs is not permitted under IAS 2/IAS 38 once expensed.
⚠️ Audit Flags
Auditors challenge the capitalisation vs. expense treatment for pre-approval inventory — this is a significant judgment area. If a company capitalises pre-approval inventory and the drug is subsequently rejected or delayed, the impairment is immediate and material. Review the regulatory certainty assessment at the manufacturing date. For drugs with high prior probability of approval (Phase III data accepted, no CMC issues), a carefully constructed capitalisation argument may be appropriate but requires robust supporting analysis. Confirm that any capitalised pre-approval inventory is impaired immediately on receipt of a CRL (Complete Response Letter).
📄 Required Documentation
Regulatory risk assessment at the time of manufacturing decision, FDA correspondence and PDUFA action date confirmation, pre-approval inventory accounting policy, manufacturing cost records, impairment assessment trigger documentation (CRL or approval), and R&D expense classification journal with project code reference.
Professional Excel Template
Get the automated version of this entry. Includes built-in IFRS checks, VAT calculators, and SAP-ready upload formats.
Expert Analysis by Qusai Ahmad
General Accountant Supervisor & IFRS Specialist
Specialized in SAP GUI automation and Middle Eastern tax compliance. Building digital tools for the next generation of finance leaders.